bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Tables from The Prediction of Clinical Outcome in Hepatocellular Carcinoma Based on a Six-Gene Metastasis Signature
Authors: Yuan Shengxian , Wang Jie , Yang Yuan , Zhang Jin , Liu Hui , Xiao Juanjuan , Xu Qingguo , Huang Xinhui , Xiang Bangde , Zhu Shaoliang , Li Lequn , Liu Jingfeng , Liu Lei , Zhou Weiping
Published: April 2023

Table S1. The gene list of potential biomarkers. Table S2. Clinical characteristics of three bathes of HCC patients from Shanghai cohort. Table S3. Performance of candidate genes to predict HCC metastasis in leave-one-out cross-validation. Table S4. Expression patterns of candidate genes in three bathes of EHBH-Sh samples. Table S5. Univariate analysis of potential biomarkers using logistic regression in 57 Sh-PCR HCC samples. Table S6. The validation of metastasis model using leave-one-gene-out method. Table S7. Univariate Cox analysis of the probability of HCC metastasis and clinicopathological variables.
Supplementary Figures from The Prediction of Clinical Outcome in Hepatocellular Carcinoma Based on a Six-Gene Metastasis Signature
Authors: Yuan Shengxian , Wang Jie , Yang Yuan , Zhang Jin , Liu Hui , Xiao Juanjuan , Xu Qingguo , Huang Xinhui , Xiang Bangde , Zhu Shaoliang , Li Lequn , Liu Jingfeng , Liu Lei , Zhou Weiping
Published: April 2023

Figure S1. Hierarchical clustering of HCC samples using differentially expressed mRNAs and/or lncRNAs. Figure S2. Hierarchical clustering of HCC samples using relative expression of seven candidates. Figure S3. Overall survival (OS) curve of HCC patients in Sh-PCR. Figure S4. The subgroups of HCC patients based on the metastasis signature. Figure S5. The predicted probability of HCC metastasis in LCI-Sh cohort. Figure S6. Survival curves in a subgroup of single-nodular HCC patients.
Supplementary Material from First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Gluck Larry , Martin Lainie P. , Olszanski Anthony J. , Tolcher Anthony W. , Ngarmchamnanrith Gataree , Rasmussen Erik , Amore Benny M. , Nagorsen Dirk , Hill John S. , Stephenson Joe
Published: April 2023

The Supplementary Material includes the full inclusion and exclusion criteria and additional methods for the skin punch biopsy. Supplementary Table 1 lists AMG 820 pharmacokinetic parameters, Figure S1 shows AMG 820 trough concentrations, Figure S2 shows AMG 820 and CSF1 concentration profiles, Figure S3 shows time-profile plots for IL-34 and TRAP5b, and Figure S4 shows skin punch biopsy images with staining for CD68 and CD115.
Figure S2 from In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development
Authors: Jaworski Felipe M. , Gentilini Lucas D. , Gueron Geraldine , Meiss Roberto P. , Ortiz Emiliano G. , Berguer Paula M. , Ahmed Asif , Navone Nora , Rabinovich Gabriel A. , Compagno Daniel , Laderach Diego J. , Vazquez Elba S.
Published: April 2023

Expression of CD146 mRNA levels in control and hemin-treated BAEC (50 μM, 8 h), as determined by RT-qPCR. Bovine GAPDH was used as an internal reference gene. * indicates P<0.05
Supplementary Table S1 from An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma
Authors: Citron Francesca , Armenia Joshua , Franchin Giovanni , Polesel Jerry , Talamini Renato , D'Andrea Sara , Sulfaro Sandro , Croce Carlo M. , Klement William , Otasek David , Pastrello Chiara , Tokar Tomas , Jurisica Igor , French Deborah , Bomben Riccardo , Vaccher Emanuela , Serraino Diego , Belletti Barbara , Vecchione Andrea , Barzan Luigi , Baldassarre Gustavo
Published: April 2023

Supplementary Table S1: Molecular and Pathological variables of patients included in the discovery cohort.
Supplementary Data from An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma
Authors: Citron Francesca , Armenia Joshua , Franchin Giovanni , Polesel Jerry , Talamini Renato , D'Andrea Sara , Sulfaro Sandro , Croce Carlo M. , Klement William , Otasek David , Pastrello Chiara , Tokar Tomas , Jurisica Igor , French Deborah , Bomben Riccardo , Vaccher Emanuela , Serraino Diego , Belletti Barbara , Vecchione Andrea , Barzan Luigi , Baldassarre Gustavo
Published: April 2023

Supplementary Figure S1. Validation of differentially expressed miRs in the discovery dataset. Supplementary Figure S2. Design of a recurrence prediction model in HNSCC based on miRs expression using a bioinformatic approach. Supplementary Figure S3. In vitro validation of miR-9 putative targets Supplementary Figure S4. Validation of putative miRs seed sites in the 3'-UTR of SASH1 and SP1 genes Supplementary Figure S5. The combined expression of miRs-1, 133a and -150 is necessary to downregulate SP1 mRNA and protein levels. Supplementary Figure S6. Correlation analyses of miRs putative targets in primary HNSCC collected in our Institute and described in Supplementary table S2 as validation set. Supplementary Figure S7. Prognostic significance of 4 miRs-targets in the TCGA HNSCC dataset. Supplementary Table S3. Median miRs' expression (qRT-PCR) according to selected characteristics Supplementary Experimental Procedures
Supplementary Figure S4 from A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients
Authors: van Vlodrop Iris J.H. , Joosten Sophie C. , De Meyer Tim , Smits Kim M. , Van Neste Leander , Melotte Veerle , Baldewijns Marcella M.L.L. , Schouten Leo J. , van den Brandt Piet A. , Jeschke Jana , Yi Joo Mi , Schuebel Kornel E. , Ahuja Nita , Herman James G. , Aarts Maureen J. , Bosman Fred T. , Van Criekinge Wim , van Engeland Manon
Published: April 2023

Supplementary Figure S4. Cause-specific overall survival curves for GREM1, LAD1, NEFH, and NEURL in hospital- and population-based ccRCC series (related to Table 1 and Table 2). Kaplan-Meier curves of GREM1 (A, B), LAD1 (C, D), NEFH (E, F) and NEURL (G, H) analyzed for overall survival in hospital- (left panels) and population-based series (right panels). Number at risk: number of patients surviving at each time point. U: unmethylated; M: methylated.
Supplementary Figure 1 from The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer
Authors: Governa Valeria , Trella Emanuele , Mele Valentina , Tornillo Luigi , Amicarella Francesca , Cremonesi Eleonora , Muraro Manuele Giuseppe , Xu Hui , Droeser Raoul , Däster Silvio R. , Bolli Martin , Rosso Raffaele , Oertli Daniel , Eppenberger-Castori Serenella , Terracciano Luigi M. , Iezzi Giandomenica , Spagnoli Giulio C.
Published: April 2023

Comparative phenotypic analysis of peripheral blood neutrophils from healthy donors and patients with CRC.
Supplementary methods, figures 1-4 and tables 1-2 from miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway
Authors: Samaeekia Ravand , Adorno-Cruz Valery , Bockhorn Jessica , Chang Ya-Fang , Huang Simo , Prat Aleix , Ha Nahun , Kibria Golam , Huo Dezheng , Zheng Hui , Dalton Rachel , Wang Yuhao , Moskalenko Grigoriy Y. , Liu Huiping
Published: April 2023

Supplementary Figure 1: miR-206 arrests cell cycle and induces apoptosis in ER positive breast cancer cells. Supplementary Figure 2. A. Transwell invasion assays of BT-20 cells transfected with miR-206 showed inhibition as compared to scramble controls. * p<0.05 Supplementary Figure 3. Gene analyses by PCR and migration Supplementary Figure 4. Effects of miR-206/siIL11 on CD44 of PDX Supplementary Table 1 Microarray results showing genes down-regulated when miR-206 is overexpressed in MDA-MB-231 cell lines. Three replicate samples of miR-206 overexpression were compared to three replicates of scramble control and three replicates of mock transfections. Supplementary Table 2 Weak, inverse correlations were observed between expression of miR-206 and expression of TWF1 in all 1300 breast cancer patients and in 354 patients with the luminal A subtype of breast cancer.
Tables S1 and S2 from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
Authors: London Cheryl A. , Gardner Heather L. , Rippy Sarah , Post Gerald , La Perle Krista , Crew Linda , Lopresti-Morrow Lori , Garton Andrew J. , McMahon Gerald , LaVallee Theresa M. , Gedrich Richard
Published: April 2023

Table S1: KTN0158 Dosing Cohorts Table S2: Summary of Anti-KTN0158 Antibody Titers in Dogs with Mast Cell Tumors Following KTN0158 Treatment
Supplementary Data from Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings
Authors: Huang Rui-Lan , Su Po-Hsuan , Liao Yu-Ping , Wu Tzu-I , Hsu Ya-Ting , Lin Wei-Yu , Wang Hui-Chen , Weng Yu-Chun , Ou Yu-Che , Huang Tim Hui-Ming , Lai Hung-Cheng
Published: April 2023

Supplementary Figure S1. Test of the methylation status of candidate genes used pooled DNA from endometrial tissues and cervical scrapings. Supplementary Figure S2. Verification of 14 candidate genes in the pilot set of cervical scrapings. Supplementary Table S1: Demographics relating to the two data sets of genome-wide DNA methylation. Supplementary Table S2. Demographics related to the clinical samples. Supplementary Table S3: Summary the area under the receiver-operating characteristic curve for distinction between endometrial cancer and noncarcinoma samples in pilot testing. Supplementary Table S4: Summary of cophenetic correlation results for analysis of consensus clustering of DNA methylation patterns. Supplementary Table S5: List of 180 hypermethylated genes in four clusters. Supplementary Table S6. Summary of the methylation levels of four candidate genes in cervical scrapings from endometrial cancer and noncarcinoma samples.
Figure S1 from Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway
Authors: Mei Qian , Li Xiang , Zhang Kang , Wu Zhiqiang , Li Xiaolei , Meng Yuanguang , Guo Mingzhou , Luo Guangbin , Fu Xiaobing , Han Weidong
Published: April 2023

Figure S1. Expression Levels of miRNAs within the Chromosomal Instability Site chr9q33.3
Figure S1 from Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay
Authors: Wang Lisha , Harms Paul W. , Palanisamy Nallasivam , Carskadon Shannon , Cao Xuhong , Siddiqui Javed , Patel Rajiv M. , Zelenka-Wang Sylvia , Durham Alison B. , Fullen Douglas R. , Harms Kelly L. , Su Fengyun , Shukla Sudhanshu , Mehra Rohit , Chinnaiyan Arul M.
Published: April 2023

Representative microphotographs of samples showing different MCPyV RNA in situ hybridization (RNA-ISH) intensity (400X magnification)
Supplementary information from Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma
Authors: Zhang Bin , Tian Jie , Dong Di , Gu Dongsheng , Dong Yuhao , Zhang Lu , Lian Zhouyang , Liu Jing , Luo Xiaoning , Pei Shufang , Mo Xiaokai , Huang Wenhui , Ouyang Fusheng , Guo Baoliang , Liang Long , Chen Wenbo , Liang Changhong , Zhang Shuixing
Published: April 2023

1. A predefined hypothesis and rationale for sample size 2. The inclusion and exclusion criteria of this study 3. Magnetic resonance image acquisition parameters 4. Supplementary methods 5. A detailed description of the LASSO method 6. Radiomics score (Rad-score) calculation formula 7. Radiomics composition in this study 8. Supplementary figures 8.1 Figure S1. Recruitment pathways for patients with advance nasopharyngeal carcinoma 8.2 Figure S2. Stratified analyses were performed to estimate progression-free survival in various subgroups, comparing high-risk patients and low-risk patients 8.3 Figure S3. Rad-score for each patient in the training cohort 9. Supplementary tables 9.1 Table S1. Radiomics feature selection results based on the cross-validation 9.2 Table S2. The mean values of radiomics features associated with tumor stages
Table S1 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Authors: Pham Lan V. , Huang Shengjian , Zhang Hui , Zhang Jun , Bell Taylor , Zhou Shouhao , Pogue Elizabeth , Ding Zhiyong , Lam Laura , Westin Jason , Davis R. Eric , Young Ken H. , Medeiros L. Jeffrey , Ford Richard J. , Nomie Krystle , Zhang Leo , Wang Michael
Published: April 2023

Up and downregulated proteins in Mino cells treated with 5 nM of venetoclax for 24 h, analyzed by RPPA analysis. Highlighted boxes show commonly altered proteins between Mino cells treated with venetoclax and DLBCL cell lines treated with venetoclax.
Supplemental figures from Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer
Authors: Shelar Sandeep , Shim Eun-Hee , Brinkley Garrett J. , Kundu Anirban , Carobbio Francesca , Poston Tyler , Tan Jubilee , Parekh Vishwas , Benson Daniel , Crossman David K. , Buckhaults Phillip J. , Rakheja Dinesh , Kirkman Richard , Sato Yusuke , Ogawa Seishi , Dutta Shilpa , Velu Sadanandan E. , Emberley Ethan , Pan Alison , Chen Jason , Huang Tony , Absher Devin , Becker Anja , Kunick Conrad , Sudarshan Sunil
Published: April 2023

Supplemental figures
Supplemental Figure Legends and Tables from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Authors: Mehrotra Shailly , Gopalakrishnan Mathangi , Gobburu Jogarao , Ji Jiuping , Greer Jacqueline M. , Piekarz Richard , Karp Judith E. , Pratz Keith W. , Rudek Michelle A.
Published: April 2023

7 tables and 3 figure legends
Supplementary Table S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER+/HER2− Breast Cancer
Authors: van der Velden Bas H.M. , Elias Sjoerd G. , Bismeijer Tycho , Loo Claudette E. , Viergever Max A. , Wessels Lodewyk F.A. , Gilhuijs Kenneth G.A.
Published: April 2023

Competing risk analysis; Cox proportional hazards models are shown for overall survival, breastâ€�cancer related death, and nonâ€�breast cancer related death. For each model, pooled hazard ratios (HR) and 95% confidence intervals (CI) are shown. Contralateral parenchymal enhancement was inverse probability weightingâ€� adjusted for age, tumor diameter on MRI, histological grade, axillary load, and systemic treatment. Pooled Pâ€�values are shown for a trendâ€�test between all three groups, intermediate CPE versus low CPE, and high CPE versus low CPE.
Table S1 from Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
Authors: Beglyarova Natalya , Banina Eugenia , Zhou Yan , Mukhamadeeva Ramilia , Andrianov Grigorii , Bobrov Egor , Lysenko Elena , Skobeleva Natalya , Gabitova Linara , Restifo Diana , Pressman Max , Serebriiskii Ilya G. , Hoffman John P. , Paz Keren , Behrens Diana , Khazak Vladimir , Jablonski Sandra A. , Golemis Erica A. , Weiner Louis M. , Astsaturov Igor
Published: April 2023

AUC results of the drug sensitivity screens in conditionally reprogrammed PDAC cells.
Figure S6 from Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
Authors: Beglyarova Natalya , Banina Eugenia , Zhou Yan , Mukhamadeeva Ramilia , Andrianov Grigorii , Bobrov Egor , Lysenko Elena , Skobeleva Natalya , Gabitova Linara , Restifo Diana , Pressman Max , Serebriiskii Ilya G. , Hoffman John P. , Paz Keren , Behrens Diana , Khazak Vladimir , Jablonski Sandra A. , Golemis Erica A. , Weiner Louis M. , Astsaturov Igor
Published: April 2023

Supplemental data for Figure 4.
Suppl Fig legends from Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53
Authors: Kenny Timothy C. , Schmidt Hank , Adelson Kerin , Hoshida Yujin , Koh Anna P. , Shah Nagma , Mandeli John , Ting Jess , Germain Doris
Published: April 2023

Supplementary figure legends
Figure S1 from Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
Authors: Beglyarova Natalya , Banina Eugenia , Zhou Yan , Mukhamadeeva Ramilia , Andrianov Grigorii , Bobrov Egor , Lysenko Elena , Skobeleva Natalya , Gabitova Linara , Restifo Diana , Pressman Max , Serebriiskii Ilya G. , Hoffman John P. , Paz Keren , Behrens Diana , Khazak Vladimir , Jablonski Sandra A. , Golemis Erica A. , Weiner Louis M. , Astsaturov Igor
Published: April 2023

Supplemental Figure S1. Rapid derivation of PDAC cells in culture
Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma
Authors: Pires da Silva Inês , Wang Kevin Y.X. , Wilmott James S. , Holst Jeff , Carlino Matteo S. , Park John J. , Quek Camelia , Wongchenko Matthew , Yan Yibing , Mann Graham , Johnson Douglas B. , McQuade Jennifer L. , Rai Rajat , Kefford Richard F. , Rizos Helen , Scolyer Richard A. , Yang Jean Y.H. , Long Georgina V. , Menzies Alexander M.
Published: April 2023

Supplementary Tables 1-2, and Figures 1-5.
Figure S3 from Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects
Authors: Meijer Titia G. , Verkaik Nicole S. , Sieuwerts Anieta M. , van Riet Job , Naipal Kishan A.T. , van Deurzen Carolien H.M. , den Bakker Michael A. , Sleddens Hein F.B.M. , Dubbink Hendrikus-Jan , den Toom T. Dorine , Dinjens Winand N.M. , Lips Esther , Nederlof Petra M. , Smid Marcel , van de Werken Harmen J.G. , Kanaar Roland , Martens John W.M. , Jager Agnes , van Gent Dik C.
Published: April 2023

Comparison of mutational signature analysis using all WGS-derived somatic mutations versus using somatic mutations present on SureSelect v5 target regions only.
supplementary figure legends from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
Authors: Gulati Pratiksha , Rühl Julia , Kannan Abhilash , Pircher Magdalena , Schuberth Petra , Nytko Katarzyna J. , Pruschy Martin , Sulser Simon , Haefner Mark , Jensen Shawn , Soltermann Alex , Jungraithmayr Wolfgang , Eisenring Maya , Winder Thomas , Samaras Panagiotis , Tabor Annett , Stenger Rene , Stupp Roger , Weder Walter , Renner Christoph , Münz Christian , Petrausch Ulf
Published: April 2023

supplementary figure legends
Figure S1 from Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects
Authors: Meijer Titia G. , Verkaik Nicole S. , Sieuwerts Anieta M. , van Riet Job , Naipal Kishan A.T. , van Deurzen Carolien H.M. , den Bakker Michael A. , Sleddens Hein F.B.M. , Dubbink Hendrikus-Jan , den Toom T. Dorine , Dinjens Winand N.M. , Lips Esther , Nederlof Petra M. , Smid Marcel , van de Werken Harmen J.G. , Kanaar Roland , Martens John W.M. , Jager Agnes , van Gent Dik C.
Published: April 2023

Workflow of functional RECAP test and molecular analyses
Table S2 from Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Authors: Delord Jean-Pierre , Robert Caroline , Nyakas Marta , McArthur Grant A. , Kudchakar Ragini , Mahipal Amit , Yamada Yasuhide , Sullivan Ryan , Arance Ana , Kefford Richard F. , Carlino Matteo S. , Hidalgo Manuel , Gomez-Roca Carlos , Michel Daniela , Seroutou Abdelkader , Aslanis Vassilios , Caponigro Giordano , Stuart Darrin D. , Moutouh-de Parseval Laure , Demuth Tim , Dummer Reinhard
Published: April 2023

Dose-limiting toxicities occurring during cycle 1 in the dose-determining set by dose group, listed per patient.
Figure S5 from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
Authors: Gulati Pratiksha , Rühl Julia , Kannan Abhilash , Pircher Magdalena , Schuberth Petra , Nytko Katarzyna J. , Pruschy Martin , Sulser Simon , Haefner Mark , Jensen Shawn , Soltermann Alex , Jungraithmayr Wolfgang , Eisenring Maya , Winder Thomas , Samaras Panagiotis , Tabor Annett , Stenger Rene , Stupp Roger , Weder Walter , Renner Christoph , Münz Christian , Petrausch Ulf
Published: April 2023

Redirected T cells did not show persistence in the blood of tumor bearing humanized mice
Table S1 from Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Authors: Delord Jean-Pierre , Robert Caroline , Nyakas Marta , McArthur Grant A. , Kudchakar Ragini , Mahipal Amit , Yamada Yasuhide , Sullivan Ryan , Arance Ana , Kefford Richard F. , Carlino Matteo S. , Hidalgo Manuel , Gomez-Roca Carlos , Michel Daniela , Seroutou Abdelkader , Aslanis Vassilios , Caponigro Giordano , Stuart Darrin D. , Moutouh-de Parseval Laure , Demuth Tim , Dummer Reinhard
Published: April 2023

Biochemical and cellular potency of encorafenib, dabrafenib, and vemurafenib in biochemical and cell-based assays. Purified BRAF V600E kinase domain was used in the biochemical experiments, using kinase-dead MEK1 as a substrate and a phosphorylated MEK1 (Ser217/221) alpha-screen readout. A375 cells were incubated with inhibitors for 3 hours to determine the phosphorylated ERK (pERK) half maximal effective concentration (EC50) and 72 hours to determine the proliferation EC50
Figure S3 from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
Authors: Gulati Pratiksha , Rühl Julia , Kannan Abhilash , Pircher Magdalena , Schuberth Petra , Nytko Katarzyna J. , Pruschy Martin , Sulser Simon , Haefner Mark , Jensen Shawn , Soltermann Alex , Jungraithmayr Wolfgang , Eisenring Maya , Winder Thomas , Samaras Panagiotis , Tabor Annett , Stenger Rene , Stupp Roger , Weder Walter , Renner Christoph , Münz Christian , Petrausch Ulf
Published: April 2023

Immune modulatory ligand expression on the investigated tumor cell line
Figure S1 from Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Authors: Delord Jean-Pierre , Robert Caroline , Nyakas Marta , McArthur Grant A. , Kudchakar Ragini , Mahipal Amit , Yamada Yasuhide , Sullivan Ryan , Arance Ana , Kefford Richard F. , Carlino Matteo S. , Hidalgo Manuel , Gomez-Roca Carlos , Michel Daniela , Seroutou Abdelkader , Aslanis Vassilios , Caponigro Giordano , Stuart Darrin D. , Moutouh-de Parseval Laure , Demuth Tim , Dummer Reinhard
Published: April 2023

Proliferation half maximal inhibitory concentration (IC50) of encorafenib, dabrafenib, and vemurafenib against a panel of BRAF V600-mutant melanoma and colorectal cell lines. Red squares represent BRAF V600E-mutant, and blue squares represent BRAF V600D/K-mutant cell lines
Supplementary table S3 from Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis
Authors: Paauwe Madelon , Schoonderwoerd Mark J.A. , Helderman Roxan F.C.P. , Harryvan Tom J. , Groenewoud Arwin , van Pelt Gabi W. , Bor Rosalie , Hemmer Danielle M. , Versteeg Henri H. , Snaar-Jagalska B. Ewa , Theuer Charles P. , Hardwick James C.H. , Sier Cornelis F.M. , ten Dijke Peter , Hawinkels Lukas J.A.C.
Published: April 2023

qPCR primer sequences.
Supplementary table S2 from Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis
Authors: Paauwe Madelon , Schoonderwoerd Mark J.A. , Helderman Roxan F.C.P. , Harryvan Tom J. , Groenewoud Arwin , van Pelt Gabi W. , Bor Rosalie , Hemmer Danielle M. , Versteeg Henri H. , Snaar-Jagalska B. Ewa , Theuer Charles P. , Hardwick James C.H. , Sier Cornelis F.M. , ten Dijke Peter , Hawinkels Lukas J.A.C.
Published: April 2023

Antibodies for immunohistochemistry, immunofluorescence and western blot.
Figure S1 and S2 from An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia
Authors: Zheng Bing , Yu Shang-Fan , del Rosario Geoffrey , Leong Steven R. , Lee Genee Y. , Vij Rajesh , Chiu Cecilia , Liang Wei-Ching , Wu Yan , Chalouni Cecile , Sadowsky Jack , Clark Vanessa , Hendricks Angela , Poon Kirsten Achilles , Chu Wayne , Pillow Thomas , Schutten Melissa M. , Flygare John , Polson Andrew G.
Published: April 2023

S1: Comparison of CLL-1 and CD33 expression level in 70 AML patients. S2: Internalization and locolization of anti-CLL-1 antibody
Supplementary figure S1 from Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis
Authors: Paauwe Madelon , Schoonderwoerd Mark J.A. , Helderman Roxan F.C.P. , Harryvan Tom J. , Groenewoud Arwin , van Pelt Gabi W. , Bor Rosalie , Hemmer Danielle M. , Versteeg Henri H. , Snaar-Jagalska B. Ewa , Theuer Charles P. , Hardwick James C.H. , Sier Cornelis F.M. , ten Dijke Peter , Hawinkels Lukas J.A.C.
Published: April 2023

Endoglin is expressed by CAFs, does not correlate to stage-III CRC patient survival and TCGA database analysis
Supplementary Tables S5, S6 from Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Authors: Spino Marissa , Kurz Sylvia C. , Chiriboga Luis , Serrano Jonathan , Zeck Briana , Sen Namita , Patel Seema , Shen Guomiao , Vasudevaraja Varshini , Tsirigos Aristotelis , Suryadevara Carter M. , Frenster Joshua D. , Tateishi Kensuke , Wakimoto Hiroaki , Jain Rajan , Riina Howard A. , Nicolaides Theodore P. , Sulman Erik P. , Cahill Daniel P. , Golfinos John G. , Isse Kumiko , Saunders Laura R. , Zagzag David , Placantonakis Dimitris G. , Snuderl Matija , Chi Andrew S.
Published: April 2023

Summary of IHC of glioma subtypes
Supplementary Figure legends from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape
Authors: Wang Zixing , Kim Tae Beom , Peng Bo , Karam Jose , Creighton Chad , Joon Aron , Kawakami Fumi , Trevisan Patricia , Jonasch Eric , Chow Chi-Wan , Canales Jaime Rodriguez , Tamboli Pheroze , Tannir Nizar , Wood Christopher , Monzon Federico , Baggerly Keith , Varella-Garcia Marileila , Czerniak Bogdan , Wistuba Ignacio , Mills Gordon , Shaw Kenna , Chen Ken , Sircar Kanishka
Published: April 2023

Figure legends for Figures S1-S10
Supplemental Table 3 from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Parseghian Christine M. , Parikh Nila U. , Wu Ji Yuan , Jiang Zhi-Qin , Henderson Laura , Tian Feng , Pastor Brice , Ychou Marc , Raghav Kanwal , Dasari Arvind , Fogelman David R. , Katsiampoura Anastasia D. , Menter David G. , Wolff Robert A. , Eng Cathy , Overman Michael J. , Thierry Alain R. , Gallick Gary E. , Kopetz Scott
Published: April 2023

Prespecified dose modifications for adverse events related to study drug in Phase IB and Phase II.
Supplementary tables from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Authors: Kang Ya'an , Roife David , Lee Yeonju , Lv Hailong , Suzuki Rei , Ling Jianhua , Rios Perez Mayrim V. , Li Xinqun , Dai BingBing , Pratt Michael , Truty Mark J. , Chatterjee Deyali , Wang Huamin , Thomas Ryan M. , Wang Yu , Koay Eugene J. , Chiao Paul J. , Katz Matthew H. , Fleming Jason B.
Published: April 2023

Supplementary Table 1. Wild type and mutant lumican SBE oligos for EMSA. Supplementary Table 2. Clinicopathologic and oncologic outcome correlation of stromal lumican expression in PDAC. Supplementary Table 3. Amount of Lumican Secretion in HPSC and PDACs Supernatant at 8 and 24 hours.
Supplemental Figure Legends from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Parseghian Christine M. , Parikh Nila U. , Wu Ji Yuan , Jiang Zhi-Qin , Henderson Laura , Tian Feng , Pastor Brice , Ychou Marc , Raghav Kanwal , Dasari Arvind , Fogelman David R. , Katsiampoura Anastasia D. , Menter David G. , Wolff Robert A. , Eng Cathy , Overman Michael J. , Thierry Alain R. , Gallick Gary E. , Kopetz Scott
Published: April 2023

Supplemental Figure Legends
Supplementary figure 2 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Authors: Kang Ya'an , Roife David , Lee Yeonju , Lv Hailong , Suzuki Rei , Ling Jianhua , Rios Perez Mayrim V. , Li Xinqun , Dai BingBing , Pratt Michael , Truty Mark J. , Chatterjee Deyali , Wang Huamin , Thomas Ryan M. , Wang Yu , Koay Eugene J. , Chiao Paul J. , Katz Matthew H. , Fleming Jason B.
Published: April 2023

Lumican expression and secretion in HPaSteC with or without TGF-β exposure at 8 and 24 hours.
Supplementary figure 1 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Authors: Kang Ya'an , Roife David , Lee Yeonju , Lv Hailong , Suzuki Rei , Ling Jianhua , Rios Perez Mayrim V. , Li Xinqun , Dai BingBing , Pratt Michael , Truty Mark J. , Chatterjee Deyali , Wang Huamin , Thomas Ryan M. , Wang Yu , Koay Eugene J. , Chiao Paul J. , Katz Matthew H. , Fleming Jason B.
Published: April 2023

Vectra Image analysis workflow, Double IF staining of lumican and collagen I, and TGF-β secretion in HPSC.
Supplementary Figure S4 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
Authors: Shattuck-Brandt Rebecca L. , Chen Sheau-Chiann , Murray Emily , Johnson Christopher Andrew , Crandall Holly , O'Neal Jamye F. , Al-Rohil Rami Nayef , Nebhan Caroline A. , Bharti Vijaya , Dahlman Kimberly B. , Ayers Gregory D. , Yan Chi , Kelley Mark C. , Kauffmann Rondi M. , Hooks Mary , Grau Ana , Johnson Douglas B. , Vilgelm Anna E. , Richmond Ann
Published: April 2023

Supplementary Figure S4: Protein Expression Patterns Did Not Predict KRT-232 Responsiveness in Group III PDX lines Compared to Group II PDX Lines
Supplementary Data Figure S3 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Authors: Tuxen Ida Viller , Rohrberg Kristoffer Staal , Oestrup Olga , Ahlborn Lise Barlebo , Schmidt Ane Yde , Spanggaard Iben , Hasselby Jane P. , Santoni-Rugiu Eric , Yde Christina Westmose , Mau-Sørensen Morten , Nielsen Finn Cilius , Lassen Ulrik
Published: April 2023

Potentiel actionable targets divided in cancer subtypes
Figure S1 from In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model
Authors: De La Maza Luis , Wu Matthew , Wu Licun , Yun Hana , Zhao Yidan , Cattral Mark , McCart Andrea , Cho BC John , de Perrot Marc
Published: April 2023

The AE17 and AB12 cell lines do not express PD-L1
Supplementary Figures 1-5 from Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer
Authors: Malchers Florian , Ercanoglu Meryem , Schütte Daniel , Castiglione Roberta , Tischler Verena , Michels Sebastian , Dahmen Ilona , Brägelmann Johannes , Menon Roopika , Heuckmann Johannes M. , George Julie , Ansén Sascha , Sos Martin L. , Soltermann Alex , Peifer Martin , Wolf Jürgen , Büttner Reinhard , Thomas Roman K.
Published: April 2023

Supplementary Figure 1 Short Tandem Repeat Analysis for H1581 and DMS114 Cells; Supplementary Figure 2 Genomic Alteration Validation of NRAS and DUSP6; Supplementary Figure 3 Genomic Differences in DMS114 and DMS114_BGJp Cells; Supplementary Figure 4 Transcriptional Change of DMS114 and DMS114_BGJr; Supplementary Figure 5 Analysis of a Patient with a Relapse under BGJ398
Supplementary Figure S1 from CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma
Authors: Stracquadanio Giovanni , Vrugt Bart , Flury Renata , Schraml Peter , Würl Peter , Müller Thomas H. , Knippschild Uwe , Henne-Bruns Doris , Breitenstein Stefan , Clavien Pierre-Alain , Graf Rolf , Bond Gareth L. , Grochola Lukasz F.
Published: April 2023

Supplementary Figure S1
Table S1 from A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Authors: Enblad Gunilla , Karlsson Hannah , Gammelgård Gustav , Wenthe Jessica , Lövgren Tanja , Amini Rose Marie , Wikstrom Kristina I. , Essand Magnus , Savoldo Barbara , Hallböök Helene , Höglund Martin , Dotti Gianpietro , Brenner Malcolm K. , Hagberg Hans , Loskog Angelica
Published: April 2023

Detailed description of the patients and infused cells
Supplementary Tables 1-3 from Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer
Authors: Schott Anne F. , Goldstein Lori J. , Cristofanilli Massimo , Ruffini Pier Adelchi , McCanna Susan , Reuben James M. , Perez Raymond P. , Kato Giraldo , Wicha Max
Published: April 2023

Table S1. Pharmacokinetic parameters of reparixin by cohort; Table S2. Pharmacokinetic parameters of paclitaxel; Table S3. Exploratory biomarkers.
Additional Tables and Figures from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Authors: Rampling Roy , Peoples Sharon , Mulholland Paul J. , James Allan , Al-Salihi Omar , Twelves Christopher J. , McBain Catherine , Jefferies Sarah , Jackson Alan , Stewart Willie , Lindner Juha , Kutscher Sarah , Hilf Norbert , McGuigan Lesley , Peters Jane , Hill Karen , Schoor Oliver , Singh-Jasuja Harpreet , Halford Sarah E. , Ritchie James W.A.
Published: April 2023

Supplementary Table S1. TUMAPs contained in IMA950 and associated source antigens. Supplementary Table S2. Statistical analysis underlying the recruitment of 20 immune evaluable patients per cohort. Supplementary Table S3. Reasons for HLA-A*02 positive patients not entering the clinical trial. Supplementary Figure S1. Study schedule. Supplementary Figure S2. Exemplary gating strategy used for the primary multimer assay. Supplementary Figure S3. Exemplary immune responses in patients as determined by multimer assay after in vitro sensitization. Supplementary Figure S4. Apparent diffusion coefficient (ADC) in Cohort 1 at each of the four scan points.
Supplementary Methods from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Authors: de Jonge Marthe M. , Auguste Aurélie , van Wijk Lise M. , Schouten Philip C. , Meijers Matty , ter Haar Natalja T. , Smit Vincent T.H.B.M. , Nout Remi A. , Glaire Mark A. , Church David N. , Vrieling Harry , Job Bastien , Boursin Yannick , de Kroon Cor D. , Rouleau Etienne , Leary Alexandra , Vreeswijk Maaike P.G. , Bosse Tjalling
Published: April 2023

Supplementary Material and Methods
Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

The combination therapy temsirolimus and RG7388 does not affect the expression of other apoptotic/anti-apoptotic proteins
Supplementary Figure 2. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Authors: Federico Sara M. , McCarville M. Beth , Shulkin Barry L. , Sondel Paul M. , Hank Jacquelyn A. , Hutson Paul , Meagher Michael , Shafer Aaron , Ng Catherine Y. , Leung Wing , Janssen William E. , Wu Jianrong , Mao Shenghua , Brennan Rachel C. , Santana Victor M. , Pappo Alberto S. , Furman Wayne L.
Published: April 2023

This figure demonstrates the relationship between prior treatment with chimeric or humanized 14.18 K322A antibody and A) the area under the concentration curve for the antibody (AUC); B elimination half-life of the antibody (T1/2 Beta); and C) the highest observed concentration of the antibody (Cmax). Although the data in panels A and B suggest that prior exposure to ch14.18 or hu14.18K322A tends to increase the AUC and the elimination half-life, there is no significant difference between prior treatment groups using the Kruskal-Wallis non-parametric test. The data in panel C do not suggest an association between prior exposure and the peak serum concentration of the hu14.18K322A antibody.
Supplementary Figure 6 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

Effect of combined RG7388 and temsirolimus on viability of human PBMCs subpopulations
Supplementary Figure 5 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

Effect of combined RG7388 and temsirolimus on human PBMCs viability and apoptosis
Supplementary Figures from IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
Authors: McMichael Elizabeth L. , Jaime-Ramirez Alena Cristina , Guenterberg Kristan D. , Luedke Eric , Atwal Lakhvir S. , Campbell Amanda R. , Hu Zhiwei , Tatum Armika S. , Kondadasula Sri Vidya , Mo Xiaokui , Tridandapani Susheela , Bloomston Mark , Ellison E. Christopher , Williams Terence M. , Bekaii-Saab Tanios , Carson William E.
Published: April 2023

Figure S1. IL-21 enhances antibody-dependent cellular cytotoxicity of NK cells against colon cancer cell lines that over-express EGFR. Figure S2. Human NK cell IFN-γ production increases over time. Figure S3. Human NK cells secrete high levels of pro-inflammatory cyotkines/chemokines in the presence of IL-21 and cetuximab-coated AsPc1 pancreatic cancer cells. Figure S4. NK cell signal transduction is enhanced by IL-21 receptor and Fc receptor engagement by cetuximab-coated wild-type KRAS BxPc3 tumor cells. Figure S5. Transfection of human EGFR into the Panc02 cell line does not significantly affect tumor growth. Figure S6. Expression of EGFR is necessary for the efficacy of IL-21 and cetuximab. Figure S7. Depletion of monocytes does not affect the efficacy of IL-21 and cetuximab combination therapy.
Supplementary Figure 3 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

Effect of combined treatment on cell viability
Supplementary Figure 1 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

p53 knockdown in neuroblastoma cells
Supplementary Methods from DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression
Authors: Xie Victoria K. , Li Zhiwei , Yan Yongmin , Jia Zhiliang , Zuo Xiangsheng , Ju Zhenlin , Wang Jing , Du Jiawei , Xie Dacheng , Xie Keping , Wei Daoyan
Published: April 2023

Supplementary Methods
Supplemental material for Biochemical, molecular, and clinical characterization of SDHA VUS from Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance
Authors: Bannon Amber E. , Kent Jason , Forquer Isaac , Town Ajia , Klug Lillian R. , McCann Kelly , Beadling Carol , Harismendy Oliver , Sicklick Jason K. , Corless Christopher , Shinde Ujwal , Heinrich Michael C.
Published: April 2023

Supplemental tables 1 and 2, supplemental figure legends, supplemental video legend
Supplementary Tables from Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Authors: Facchinetti Francesco , Loriot Yohann , Kuo Mei-Shiue , Mahjoubi Linda , Lacroix Ludovic , Planchard David , Besse Benjamin , Farace Françoise , Auger Nathalie , Remon Jordi , Scoazec Jean-Yves , André Fabrice , Soria Jean-Charles , Friboulet Luc
Published: April 2023

Supplementary Table S1. Whole Exome Sequencing (WES) results on crizotinib resistant biopsy. Supplementary Table S2. Single base substitutions leading to ALK and ROS1 kinase domain mutations.
Supplementary Tables 1-3 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Authors: Yanagita Masahiko , Redig Amanda J. , Paweletz Cloud P. , Dahlberg Suzanne E. , O'Connell Allison , Feeney Nora , Taibi Myriam , Boucher David , Oxnard Geoffrey R. , Johnson Bruce E. , Costa Daniel B. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Table S1: Inclusion and exclusion criteria for study eligibility; Table S2: PCR primer and probe sequences; Table S3: Patient and tumor characteristics.
Supplementary Table 4 from AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Authors: Yi Xue , Sarkar Aloke , Kismali Gorkem , Aslan Burcu , Ayres Mary , Iles LaKesla R. , Keating Michael J. , Wierda William G. , Long James P. , Bertilaccio Maria Teresa Sabrina , Gandhi Varsha
Published: April 2023

Supplementary Table 4
Supplementary Information from Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Authors: Tolcher Anthony W. , Sznol Mario , Hu-Lieskovan Siwen , Papadopoulos Kyriakos P. , Patnaik Amita , Rasco Drew W. , Di Gravio Donna , Huang Bo , Gambhire Dhiraj , Chen Ying , Thall Aron D. , Pathan Nuzhat , Schmidt Emmett V. , Chow Laura Q.M.
Published: April 2023

Table S1. Patient flow by dose group Table S2. PK parameters of utomilumab following multiple dosing Figure S1. Partial response in a patient with anaplastic thyroid carcinoma (utomilumab 3.6 mg/kg + pembrolizumab 2 mg/kg) at cycle 4 versus baseline. Figure S2. Mean concentration-time profile for pembrolizumab
Supplemental Figures 1 and 2 from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution
Authors: Kraal Kathelijne C.J.M. , Timmerman Ilse , Kansen Hannah M. , van den Bos Cor , Zsiros Jozsef , van den Berg Henk , Somers Sebastiaan , Braakman Eric , Peek Annemarie M.L. , van Noesel Max M. , van der Schoot C. Ellen , Fiocco Marta , Caron Huib N. , Voermans Carlijn , Tytgat Godelieve A.M.
Published: April 2023

S1: Neutrophil recovery post ASCT S2: Clonogenic capacity harvested stem cells
Legends from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution
Authors: Kraal Kathelijne C.J.M. , Timmerman Ilse , Kansen Hannah M. , van den Bos Cor , Zsiros Jozsef , van den Berg Henk , Somers Sebastiaan , Braakman Eric , Peek Annemarie M.L. , van Noesel Max M. , van der Schoot C. Ellen , Fiocco Marta , Caron Huib N. , Voermans Carlijn , Tytgat Godelieve A.M.
Published: April 2023

Legends
Supplementary Figure 3 from Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Authors: Polk Avery , Lu Ye , Wang Tianjiao , Seymour Erlene , Bailey Nathanael G. , Singer Jack W. , Boonstra Philip S. , Lim Megan S. , Malek Sami , Wilcox Ryan A.
Published: April 2023

Treatment of monocyte-derived macrophages with pacritinib culminates in apoptosis.
Supplementary Figure 1 from Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Authors: Polk Avery , Lu Ye , Wang Tianjiao , Seymour Erlene , Bailey Nathanael G. , Singer Jack W. , Boonstra Philip S. , Lim Megan S. , Malek Sami , Wilcox Ryan A.
Published: April 2023

Generation of nurse-like cells.
Supplementary Table S4 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Cox PH Model of OS Versus Baseline RAS Mutant Allele Frequency (with cfDNA concentration normalized or unnormalized, and with WT samples included or excluded)
Figure S1 from C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes
Authors: Wang Xiaohong , Liang Qiaoyi , Zhang Lianhai , Gou Hongyan , Li Ziyu , Chen Huarong , Dong Yujuan , Ji Jiafu , Yu Jun
Published: April 2023

Eligible patients of different cohorts. Eligible patients in cohort I, cohort II, cohort III and TCGA cohort.
Supplementary Figure S6 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Emergent Mutational Profiles
Supplementary Table 1 from An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Authors: Piro Geny , Carbone Carmine , Cataldo Ivana , Di Nicolantonio Federica , Giacopuzzi Simone , Aprile Giuseppe , Simionato Francesca , Boschi Federico , Zanotto Marco , Mina Maria Mihaela , Santoro Raffaela , Merz Valeria , Sbarbati Andrea , de Manzoni Giovanni , Scarpa Aldo , Tortora Giampaolo , Melisi Davide
Published: April 2023

Top differentially regulated coding genes in N87-TR1, N87-TR2, N87-TR3, and N87-TR4 trastuzumab-resistant gastric cancer cell lines compared with NCI-N87 control cell line.
Supplementary Figure S4 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Net Change of Mutational Load
Supplementary Figure S2 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Mutation Prevalence at Baseline